Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting

References

• Feigin VL, Abajobir AA, Abate KH, et al. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol. 2017;16:877–897.
   PubMed Web of Science ®Google Scholar
• Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010). J Neurol. 2015;262:2352–2363.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Fisk JD, Stadnyk KJ, et al. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci. 2013;40:824–831.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74:465–471.
   PubMed Web of Science ®Google Scholar
• Al-Sakran LH, Marrie RA, Blackburn DF, et al. Establishing the incidence and prevalence of multiple sclerosis in Saskatchewan. Can J Neurol Sci. 2018;45:295–303.
   PubMed Web of Science ®Google Scholar
• Amankwah N, Marrie RA, Bancej C, et al. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can. 2017;37:37–48.
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–180.
   PubMed Web of Science ®Google Scholar
• Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian multiple sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PloS One. 2013;8:e59694.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:458–468.
   PubMed Web of Science ®Google Scholar
• Spelman T, Mekhael L, Burke T, et al. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Eur J Neurol. 2016;23:729–736.
   PubMedGoogle Scholar
• Hartung DM, Johnston KA, Geddes J, et al. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis. Neurology. 2020;94:e1407–e14.
   PubMed Web of Science ®Google Scholar
• Li P, Ladage VP, Berger J, et al. Disease-modifying therapy adherence and associated factors in a national sample of medicare patients with multiple sclerosis. Value Health. 2020;23(3):328–334.
   PubMed Web of Science ®Google Scholar
• Müller S, Heidler T, Fuchs A, et al. Real-world treatment of patients with multiple sclerosis per MS subtype and associated healthcare resource use: an analysis based on 13,333 patients in Germany. Neurol Ther. 2020;9:67–83.
   PubMed Web of Science ®Google Scholar
• Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public health research. Annu Rev Public Health. 2011;32:91–108.
   PubMed Web of Science ®Google Scholar
• Lucyk K, Lu M, Sajobi T, et al. Administrative health data in Canada: lessons from history. BMC Med Inform Decis Mak. 2015;15:69.
   PubMed Web of Science ®Google Scholar
• Cadarette SM, Wong L. An introduction to health care administrative data. Can J Hosp Pharm. 2015;68:232–237.
   PubMedGoogle Scholar
• Statistics Canada. Census profile, 2016 census; 2017 [cited 2020 May 27]. Available from: https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E
   Google Scholar
• British Columbia Ministry of Health [creator]. Medical services plan (MSP) payment information file. V2. Population Data BC [publisher]. Data Extract. MOH; 2017. Available from: http://www.popdata.bc.ca/data
   Google Scholar
• Canadian Institute for Health Information [creator]: Discharge abstract database (hospital separations). V2. Population Data BC [publisher]. Data Extract. MOH; 2017. Available from: http://www.popdata.bc.ca/data
   Google Scholar
• BC Ministry of Health [creator]. PharmaNet. V2. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee; 2017. Available from: http://www.popdata.bc.ca/data
   Google Scholar
• British Columbia Ministry of Health [creator]. Consolidation file (MSP Registration & premium billing). V2. Population Data BC [publisher]. Data Extract. MOH; 2017. Available from: http://www.popdata.bc.ca/data
   Google Scholar
• Canadian Institute for Health Information and Statistics Canada. Health Indicators 2013; 2013 [cited 2020 Oct 14]. Available from: https://secure.cihi.ca/free_products/HI2013_EN.pdf
   Google Scholar
• BC Vital Statistics Agency [creator]. Vital statistics deaths. V2. Population Data BC [publisher]. Data Extract BC Vital Statistics Agency; 2017. Available from: http://www.popdata.bc.ca/data
   Google Scholar
• Wijnands JMA, Zhu F, Kingwell E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;30:1050–1056.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Bernstein CN, Peschken CA, et al. Intensive care unit admission in multiple sclerosis: increased incidence and increased mortality. Neurology. 2014;82:2112–2119.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA; Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90:789–800.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Miller A, Sormani MP, et al. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology. 2016;86:1437–1445.
   PubMed Web of Science ®Google Scholar
• Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86:1287–1295.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–256.
   PubMed Web of Science ®Google Scholar
• The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–1801.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995;45:1268–1276.
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903–914.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889–897.
   PubMed Web of Science ®Google Scholar
• Rojas JI, Pappolla A, Patrucco L, et al. Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis? Mult Scler Relat Disord. 2020;39:101931.
   PubMed Web of Science ®Google Scholar
• Livingston T, Fay M, Iyer R, et al. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs. J Manag Care Spec Pharm. 2016;22:1385–1391.
   PubMed Web of Science ®Google Scholar
• Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–1357.
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Laursen B, Stenager E, et al. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry. 2017;88:626–631.
   PubMed Web of Science ®Google Scholar
• Wijnands JMA, Ekuma O, Kingwell E, et al. MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. Mult Scler Relat Disord. 2019;28:138–144.
   PubMedGoogle Scholar
• Lahdenperä S, Soilu-Hänninen M, Kuusisto H-M, et al. Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand. 2020;142(6):605–612.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Mahesri M, Gagne JJ, et al. Utilization patterns of oral disease-modifying drugs in commercially insured patients with multiple sclerosis. J Manag Care Spec Pharm. 2019;25:113–121.
   PubMed Web of Science ®Google Scholar
• Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7:263–275.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17:74–82.
   PubMedGoogle Scholar
• Bottomley C, Lloyd A, Bennett G, et al. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in multiple sclerosis. J Med Econ. 2017;20:863–870.
   PubMed Web of Science ®Google Scholar
• Hincapie AL, Penm J, Burns CF. Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis. J Manag Care Spec Pharm. 2017;23:822–830.
   PubMed Web of Science ®Google Scholar
• Frost N, Freeman J, Brixner D, et al. Patients’ preferences and willingness-to-pay for disease-modifying therapies. Mult Scler Relat Disord. 2019;35:55–60.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology. 2018;90:777–788.
   PubMed Web of Science ®Google Scholar
• Alonso R, Eizaguirre MB, Zavala L, et al. Changes in the multiple sclerosis treatment paradigm. What do we do now and what were we doing before? J Clin Neurol. 2018;14:487–491.
   PubMed Web of Science ®Google Scholar
• Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013;27:239–247.
   PubMed Web of Science ®Google Scholar
• Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn). 2019;25:715–735.
   PubMedGoogle Scholar
• Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3:545–555.
   PubMed Web of Science ®Google Scholar
• Yiannakoulias N, Schopflocher DR, Warren SA, et al. Parkinson’s disease, multiple sclerosis and changes of residence in Alberta. Can J Neurol Sci. 2007;34:343–348.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157–1168.
   PubMed Web of Science ®Google Scholar